{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:14:25Z","timestamp":1769213665868,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017667","name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clim.2026.110663","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:15:52Z","timestamp":1768436152000},"page":"110663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical prognosis and cancer risk assessment in autoimmune diseases with anti\u2013TIF1\u03b3 alone or concurrent with anti\u2013Ro52 antibodies in a Taiwanese cohort"],"prefix":"10.1016","volume":"283","author":[{"given":"Chih-Chun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clim.2026.110663_bb0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","article-title":"Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients","volume":"49","author":"Kang","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0015","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors: three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0020","first-page":"1475","article-title":"Age distribution and prevalence in different age groups of four myositis-specific autoantibodies, including anti-ARS, anti-MDA5, anti-Mi-2, and anti-TIF1\u03b3 antibodies","volume":"50","author":"Ueda-Hayakawa","year":"2023","journal-title":"J. Dermatol."},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies (anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5) in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10067-020-05274-2","article-title":"The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies","volume":"40","author":"Xu","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2026.110663_bb0035","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.jaad.2020.07.131","article-title":"Autoantibody profiles in patients\u2019 sera associated with distribution patterns of dermatomyositis skin symptoms","volume":"84","author":"Ogawa-Momohara","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0050","doi-asserted-by":"crossref","first-page":"224","DOI":"10.55563\/clinexprheumatol\/i2xeao","article-title":"A retrospective cohort study in Chinese patients with adult polymyositis and dermatomyositis: risk of comorbidities and subclassification using machine learning","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.clim.2026.110663_bb0055","first-page":"990","article-title":"Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients","volume":"36","author":"Ogawa-Momohara","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2026.110663_bb0065","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case-based comprehensive review","volume":"22","author":"Kilinc","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.clim.2026.110663_bb0070","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0075","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.23325","article-title":"Association of anti-transcription intermediary factor 1\u03b3 antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis","volume":"70","author":"Venalis","year":"2018","journal-title":"Arthritis Care Res."},{"issue":"5","key":"10.1016\/j.clim.2026.110663_bb0080","first-page":"5960","article-title":"Characteristics and predictors of malignancy in dermatomyositis: analysis of 239 patients from northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.clim.2026.110663_bb0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/BOR.0000000000000535","article-title":"The diagnostic work-up of cancer-associated myositis","volume":"30","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"issue":"9","key":"10.1016\/j.clim.2026.110663_bb0090","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0095","first-page":"443","article-title":"Treatment of refractory anti-NXP2 and anti-TIF1\u03b3 dermatomyositis with tofacitinib","volume":"19","author":"Navarro-Navarro","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0100","first-page":"e77","article-title":"Janus kinase inhibitor for anti-transcription intermediary factor 1-\u03b3 positive cancer-associated dermatomyositis","volume":"189","author":"Wu","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult-onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/art.42345","article-title":"Genetic influences in cancer-associated myositis","volume":"75","author":"Patasova","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0120","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","article-title":"TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1\u03b3 positive cancer-associated dermatomyositis","volume":"60","author":"Cordel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0125","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"Motegi","year":"2020","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s42003-021-01932-6","article-title":"Analysis of human total antibody repertoires in TIF1\u03b3 autoantibody positive dermatomyositis","volume":"4","author":"Megremis","year":"2021","journal-title":"Commun Biol."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0135","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","article-title":"Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110663_bb0140","article-title":"Machine learning algorithms identify clinical subtypes and cancer in anti-TIF1\u03b3+ myositis: a longitudinal study of 87 patients","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110663_bb0145","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1093\/rheumatology\/keab625","article-title":"Identification of distinct cytokine\/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-\u03b3 antibody","volume":"61","author":"Zhao","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.clim.2026.110663_bb0150","first-page":"3062","article-title":"Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis","volume":"62","author":"Shih","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2021.10.003","article-title":"Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1\u03b3 antibodies","volume":"104","author":"Ly","year":"2021","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"14","key":"10.1016\/j.clim.2026.110663_bb0170","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0175","first-page":"3609","article-title":"Circulating VEGF-A, TNF-\u03b1, CCL2, IL-6, and IFN-\u03b3 as biomarkers of cancer in cancer-associated anti-TIF1-\u03b3 antibody-positive dermatomyositis","volume":"41","author":"Li","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0180","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/rheumatology\/keac577","article-title":"Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study","volume":"62","author":"Cordel","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.clim.2026.110663_bb0185","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.40895","article-title":"The IgG2 isotype of anti-transcription intermediary factor 1gamma autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0190","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-gamma antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.clim.2026.110663_bb0195","article-title":"Characteristic vascular finding in TIF1-\u03b3 dermatomyositis","volume":"14","author":"Franciosi","year":"2021","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0200","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10067-020-05424-6","article-title":"Cutaneous features of anti-TIF1-\u03b3-associated dermatomyositis","volume":"40","author":"Ho","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"12","key":"10.1016\/j.clim.2026.110663_bb0205","article-title":"Ovoid palatal patch: a clue to anti-TIF1\u03b3 dermatomyositis","volume":"13","author":"Franciosi","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"9","key":"10.1016\/j.clim.2026.110663_bb0210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clim.2026.110663_bb0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdcr.2021.05.006","article-title":"Distinct purpuric lesions in patients with dermatomyositis","volume":"13","author":"Cho","year":"2021","journal-title":"JAAD Case Rep."},{"issue":"8","key":"10.1016\/j.clim.2026.110663_bb0220","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.20090585","article-title":"Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway","volume":"206","author":"Espinosa","year":"2009","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0225","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1084\/jem.20170779","article-title":"Trim33 mediates the proinflammatory function of Th17 cells","volume":"215","author":"Tanaka","year":"2018","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jdermsci.2022.09.002","article-title":"E3 ubiquitin ligase Trim33 ubiquitylates annexin A2 to promote NF-\u03baB induced skin inflammation in psoriasis","volume":"107","author":"Zhang","year":"2022","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.clim.2026.110663_bb0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2023","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-023-03100-z","article-title":"Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.clim.2026.110663_bb0245","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0250","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0255","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/08916934.2012.732131","article-title":"Clinical associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies: diagnostic utility of their separate detection","volume":"46","author":"Men\u00e9ndez","year":"2013","journal-title":"Autoimmunity"},{"issue":"11","key":"10.1016\/j.clim.2026.110663_bb0260","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1007\/s10067-022-06299-5","article-title":"Anti-Ro52\/TRIM21 serological subsets identify differential clinical and laboratory parameters","volume":"41","author":"Lee","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.clim.2026.110663_bb0265","first-page":"1933","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02522-6","article-title":"Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease","volume":"11","author":"Kuriyama","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.clim.2026.110663_bb0275","first-page":"1669","article-title":"Shared and distinctive transcriptomic and proteomic pathways in adult and juvenile dermatomyositis","volume":"75","author":"Ward","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2026.110663_bb0280","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0285","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1038\/s41598-017-09309-8","article-title":"Hypoxia triggers IFN-I production in muscle: implications in dermatomyositis","volume":"7","author":"De Luna","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.clim.2026.110663_bb0290","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","article-title":"The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3","volume":"181","author":"Higgs","year":"2008","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.clim.2026.110663_bb0295","article-title":"Trim33 conditions the lifespan of primitive macrophages and onset of definitive macrophage production","volume":"149","author":"Lou Demy","year":"2022","journal-title":"Development"},{"key":"10.1016\/j.clim.2026.110663_bb0300","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ebiom.2019.05.037","article-title":"TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammation","volume":"44","author":"Petit","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clim.2026.110663_bb0305","doi-asserted-by":"crossref","first-page":"8900","DOI":"10.1038\/ncomms9900","article-title":"TRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation","volume":"6","author":"Ferri","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0310","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cei.12914","article-title":"Ro52\/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies","volume":"188","author":"G\u00f3mez-Mart\u00edn","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2026.110663_bb0315","article-title":"TIF1\u03b3 inhibits lung adenocarcinoma EMT and metastasis by interacting with the TAF15\/TBP complex","volume":"41","author":"Su","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.clim.2026.110663_bb0320","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/ncomms7156","article-title":"Tumour suppressor TRIM33 targets nuclear \u03b2-catenin degradation","volume":"6","author":"Xue","year":"2015","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.clim.2026.110663_bb0325","article-title":"TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation","volume":"23","author":"Chen","year":"2022","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0330","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1038\/s41467-023-40847-0","article-title":"Trim33 masks a non-transcriptional function of E2f4 in replication fork progression","volume":"14","author":"Rousseau","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.clim.2026.110663_bb0335","article-title":"The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer","volume":"133","author":"Liu","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0340","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-023-36523-y","article-title":"TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.clim.2026.110663_bb0345","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12943-022-01675-w","article-title":"Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21\/ELOA\/LHPP axis in colorectal cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:27:47Z","timestamp":1769128067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162600001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":69,"alternative-id":["S152166162600001X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110663","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical prognosis and cancer risk assessment in autoimmune diseases with anti\u2013TIF1\u03b3 alone or concurrent with anti\u2013Ro52 antibodies in a Taiwanese cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110663"}}